The 2026 guidance wasn't great, revenue and earnings both declining year-over-year. COVID revenue keeps dropping, and patent expirations are hitting hard. They're saying real growth won't come back until 2029 or 2030. But I'm hoping the Metsera acquisition can bridge the gap. They paid $10 billion for obesity dr-g assets, and we should see Phase 2 results early this year. If that works out, it could be huge. The obesity dr-g market is exploding, and Pfizer needs something to fill that $20 billion revenue hole. The 6.8% dividend yield is nice while I wait, but I'm really banking on the obesity dr-gs coming through.
There are no replies in this thread yet. Be the first to post a reply below: